Cefuroxime Dosing for Cholecystitis
For acute cholecystitis in patients with normal renal function, cefuroxime should be dosed at 1.5 grams IV every 8 hours, with treatment duration of 4 days for uncomplicated cases in immunocompetent patients, or up to 7 days for complicated cases or immunocompromised/critically ill patients.
Dosing Regimen
The FDA-approved dosing for severe or complicated infections is 1.5 grams IV every 8 hours 1. This dose is specifically indicated for serious infections and aligns with the severity of acute cholecystitis requiring antibiotic therapy.
For cholecystitis specifically:
- Uncomplicated cholecystitis: If early cholecystectomy (within 7-10 days) is planned, use single-dose prophylaxis only with no post-operative antibiotics 2
- Complicated cholecystitis with adequate source control: 1.5g IV q8h for 4 days in immunocompetent, non-critically ill patients 2
- Complicated cholecystitis in critically ill/immunocompromised: 1.5g IV q8h for up to 7 days based on clinical response 2
Clinical Context and Guidelines
The 2024 Italian Council guidelines for intra-abdominal infections do not list cefuroxime as a first-line agent for cholecystitis 2. For non-critically ill immunocompetent patients with adequate source control, they recommend amoxicillin/clavulanate 2g/0.2g q8h, while critically ill patients should receive piperacillin/tazobactam 2. However, cefuroxime remains an acceptable second-generation cephalosporin alternative, particularly when first-line agents are unavailable or contraindicated.
Cefuroxime achieves therapeutic concentrations in gallbladder wall tissue (the primary site of inflammation) and bile, even with cystic duct obstruction, as it diffuses from the bloodstream 3. This pharmacokinetic property makes it suitable for biliary infections.
Duration of Therapy
Stop antibiotics after 4 days if:
- Source control is adequate (successful cholecystectomy)
- Patient is immunocompetent and not critically ill
- Clinical improvement is evident 2
Extend to 7 days if:
- Patient is immunocompromised or critically ill
- Ongoing signs of infection persist
- Source control is delayed or inadequate 2
Any patient with ongoing signs of infection beyond 7 days warrants diagnostic re-evaluation 2.
Renal Dosing Adjustments
For patients with renal impairment, adjust as follows 1:
- CrCl >20 mL/min: 750mg-1.5g q8h (standard dosing)
- CrCl 10-20 mL/min: 750mg q12h
- CrCl <10 mL/min: 750mg q24h
- Hemodialysis: Additional dose after dialysis
Important Caveats
Cefuroxime is not a guideline-recommended first-line agent for cholecystitis. Recent evidence shows only 45% adherence to IDSA-recommended antibiotics (cefazolin, ceftriaxone, or cefuroxime) for mild-to-moderate cholecystitis 4. While cefuroxime is listed as an acceptable option, cefazolin or ceftriaxone are preferred for community-acquired biliary infections due to better guideline support.
For surgical prophylaxis in cardiac or vascular surgery, cefuroxime dosing is 1.5g IV plus 0.75g in priming, with reinjection of 0.75g every 2 hours intraoperatively 5. However, for cholecystectomy prophylaxis specifically, single-dose cefazolin is the standard 2.
The most common pathogens in acute cholecystitis are E. coli, Klebsiella, Streptococcus, and Enterococcus species 6. Cefuroxime provides adequate coverage for most community-acquired biliary pathogens, though it lacks reliable enterococcal coverage—this is generally acceptable as enterococcal coverage is not routinely required for community-acquired infections unless the patient is immunosuppressed 7.